RenovoRx, Inc. Files 2024 10-K

Ticker: RNXT · Form: 10-K · Filed: Apr 1, 2025 · CIK: 1574094

Renovorx, INC. 10-K Filing Summary
FieldDetail
CompanyRenovorx, INC. (RNXT)
Form Type10-K
Filed DateApr 1, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

RenovoRx dropped its 2024 10-K. Check financials for FY ending 12/31/24.

AI Summary

RenovoRx, Inc. filed its 2024 10-K on April 1, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in Mountain View, CA, operates in the Pharmaceutical Preparations sector. Key financial data and disclosures for the period are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of RenovoRx's financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, RenovoRx faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of RenovoRx, Inc.?

RenovoRx, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].

When did RenovoRx, Inc. file its 10-K report?

RenovoRx, Inc. filed its 10-K report on April 1, 2025.

For which fiscal year is this 10-K report?

This 10-K report covers the fiscal year ending December 31, 2024.

Where is RenovoRx, Inc. located?

RenovoRx, Inc.'s business address is located at 2570 W. El Camino Real, Ste. 320, Mountain View, CA 94040.

What is the SEC file number for RenovoRx, Inc.?

The SEC file number for RenovoRx, Inc. is 001-40738.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on April 1, 2025 regarding RenovoRx, Inc. (RNXT).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing